Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Florida Retina Institute
mi
from
Orlando, FL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Florida Retina Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Fort Lauderdale Eye Institute
mi
from
Plantation, FL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Fort Lauderdale Eye Institute
mi
from
Plantation, FL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Emory Eye Center
mi
from
Atlanta, GA
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Emory Eye Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Wilmer Eye Institute at Johns Hopkins
mi
from
Baltimore, MD
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Wilmer Eye Institute at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
mi
from
Detroit, MI
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
mi
from
Detroit, MI
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
The Retina Center
mi
from
Minneapolis, MN
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
The Retina Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
The New York Eye and Ear Infirmary/Faculty Eye Practice
mi
from
New York, NY
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
The New York Eye and Ear Infirmary/Faculty Eye Practice
mi
from
New York, NY
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Cleveland, Inc.
mi
from
Beachwood, OH
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Cleveland, Inc.
mi
from
Beachwood, OH
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Retina Northwest, PC
mi
from
Portland, OR
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Retina Northwest, PC
mi
from
Portland, OR
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Palmetto Retina Center
mi
from
West Columbia, SC
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Palmetto Retina Center
mi
from
West Columbia, SC
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Baylor Eye Physicians and Surgeons
mi
from
Houston, TX
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Baylor Eye Physicians and Surgeons
mi
from
Houston, TX
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Texas Retina Associates
mi
from
Lubbock, TX
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Texas Retina Associates
mi
from
Lubbock, TX
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
UBC/VCHA Eye Care Centre
mi
from
Vancouver,
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
UBC/VCHA Eye Care Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Retina Group of Florida
mi
from
Fort Lauderdale, FL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Retina Group of Florida
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
mi
from
West Monroe, LA
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
mi
from
West Monroe, LA
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Mid Atlantic Retina Specialists
mi
from
Hagerstown, MD
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Mid Atlantic Retina Specialists
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
mi
from
Pinellas Park, FL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Eye Associates of New Mexico
mi
from
Albuquerque, NM
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Eye Associates of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Gailey Eye Clinic
mi
from
Bloomington, IL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Gailey Eye Clinic
mi
from
Bloomington, IL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Oregon Retina, LLP
mi
from
Eugene, OR
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Oregon Retina, LLP
mi
from
Eugene, OR
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Southwest Retina Specialists
mi
from
Amarillo, TX
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Southwest Retina Specialists
mi
from
Amarillo, TX
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Retina Center of Texas
mi
from
Grapevine, TX
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Retina Center of Texas
mi
from
Grapevine, TX
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Shashi D Ganti, MD PC
mi
from
Porterville, CA
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Shashi D Ganti, MD PC
mi
from
Porterville, CA
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Springfield Clinic, LLP
mi
from
Springfield, IL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Springfield Clinic, LLP
mi
from
Springfield, IL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent
mi
from
Jacksonville, FL
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated:  12/31/1969
Robert E. Torti, MD, PA dba Retina Specialists
mi
from
DeSoto, TX
Anti-VEGF Treatment for Prevention of PDR/DME
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Status: Enrolling
Updated: 12/31/1969
Robert E. Torti, MD, PA dba Retina Specialists
mi
from
DeSoto, TX
Click here to add this to my saved trials
Pediatric Type 1 Diabetes and Retinopathy
Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera
Status: Enrolling
Updated:  12/31/1969
Florida Diabetes Camps
mi
from
De Leon Springs, FL
Pediatric Type 1 Diabetes and Retinopathy
Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera
Status: Enrolling
Updated: 12/31/1969
Florida Diabetes Camps
mi
from
De Leon Springs, FL
Click here to add this to my saved trials
Pediatric Type 1 Diabetes and Retinopathy
Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera
Status: Enrolling
Updated:  12/31/1969
Pediatrics Endocrinology/Diabetes at UF Health Medical Plaza and Children's Medical Services Building
mi
from
Gainesville, FL
Pediatric Type 1 Diabetes and Retinopathy
Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera
Status: Enrolling
Updated: 12/31/1969
Pediatrics Endocrinology/Diabetes at UF Health Medical Plaza and Children's Medical Services Building
mi
from
Gainesville, FL
Click here to add this to my saved trials
Pediatric Type 1 Diabetes and Retinopathy
Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera
Status: Enrolling
Updated:  12/31/1969
Children With Diabetes Friends For Life Conference
mi
from
Orlando, FL
Pediatric Type 1 Diabetes and Retinopathy
Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera
Status: Enrolling
Updated: 12/31/1969
Children With Diabetes Friends For Life Conference
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution for the Treatment of Leber's Hereditary Optic Neuropathy
A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)
Status: Enrolling
Updated:  12/31/1969
Doheny Eye Center
mi
from
Pasadena, CA
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution for the Treatment of Leber's Hereditary Optic Neuropathy
A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)
Status: Enrolling
Updated: 12/31/1969
Doheny Eye Center
mi
from
Pasadena, CA
Click here to add this to my saved trials
Epiretinal Membrane and Pseudophakic Cystoid Macular Edema
Association of Cystoid Macular Edema After Cataract Surgery in Patients With and Without Epiretinal Membrane
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Epiretinal Membrane and Pseudophakic Cystoid Macular Edema
Association of Cystoid Macular Edema After Cataract Surgery in Patients With and Without Epiretinal Membrane
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
Decentralized Pilot Study to Evaluate MyVisionTrack^TM Home Vision Testing in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Currently Receiving Intravitreal Lucentis® Therapy.
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Retina
mi
from
Salt Lake City, UT
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
Decentralized Pilot Study to Evaluate MyVisionTrack^TM Home Vision Testing in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Currently Receiving Intravitreal Lucentis® Therapy.
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Retina
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retinal Research Institute LLC
mi
from
Phoenix, AZ
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retinal Research Institute LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Associated Retina Consultants
mi
from
Phoenix, AZ
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Associated Retina Consultants
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Arizona Retina and Vitreous Consultants
mi
from
Phoenix, AZ
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Arizona Retina and Vitreous Consultants
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Associates Southwest, PC
mi
from
Tucson, AZ
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Associates Southwest, PC
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Orange County
mi
from
Fullerton, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Orange County
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
United Med Res Inst
mi
from
Inglewood, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
United Med Res Inst
mi
from
Inglewood, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Orange County
mi
from
Laguna Hills, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Orange County
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Jules Stein Eye Institute, UCLA
mi
from
Los Angeles, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Jules Stein Eye Institute, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Ophthalmic Clinical Trials San Diego
mi
from
Oceanside, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Ophthalmic Clinical Trials San Diego
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Southern CA Desert Retina Cons
mi
from
Palm Desert, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Southern CA Desert Retina Cons
mi
from
Palm Desert, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retina Consultants, San Diego
mi
from
Poway, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retina Consultants, San Diego
mi
from
Poway, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants Medical Group, Inc.
mi
from
Sacramento, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants Medical Group, Inc.
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated:  12/31/1969
Orange County Retina Medical Group
mi
from
Santa Ana, CA
A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema
A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema
Status: Enrolling
Updated: 12/31/1969
Orange County Retina Medical Group
mi
from
Santa Ana, CA
Click here to add this to my saved trials